Ikena Oncology

Ikena Oncology

  • Founded: 2016
  • Location: Boston, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin1
  • Therapy area: Oncology
  • Drug types: ONC
  • Lead product: IK-930
  • Product link: https://ikenaoncology.com/pipeline/
  • Funding: $40M stock May 2023; $144M IPO Mar 2021; $120M B Jan 2021; $80M Jan 2019; $49M Dec 2017
  • Investors: Celgene



job board

Short description:


Drug notes:

IK-175 Clin1 bladder cancer (Partner: BMS), Clin1 head & neck cancer (partner: BMS); IK-595 Clin0 oncology; 2 undisclosed programs Clin0 oncology

Long description:

Ikena Oncology is a clinical-stage biopharmaceutical company developing novel targeted therapies intended to enable a personalized approach for every patient with cancer. The company's pipeline includes programs that target key signaling pathways that drive the formation and spread of cancer, as well as programs targeting the tumor microenvironment. Ikena's lead product candidate, IK-930, is a TEAD inhibitor targeting the Hippo signaling pathway. The Hippo signaling pathway plays a critical role in regulating cell growth and survival. When the Hippo signaling pathway is disrupted, cancer cells can grow and spread uncontrollably. Ikena also has a number of other programs in preclinical and early clinical development.


Ikena Oncology
Clinical Scientist
Boston, MA|15 days ago
Ikena Oncology
Clinical Scientist
Boston, MA|24 days ago
Ikena Oncology
Sr. Clinical Trial Manager
Boston, US|60 days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com